Bio Historical Cash Flow
| BPTH Stock | USD 0.68 0.03 4.23% |
Analysis of Bio Path cash flow over time is an excellent tool to project Bio Path Holdings future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 3.3 M or Begin Period Cash Flow of 6.1 M as it is a great indicator of Bio Path ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Bio Path Holdings latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bio Path Holdings is a good buy for the upcoming year.
Bio |
About Bio Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Bio balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Bio's non-liquid assets can be easily converted into cash.
Bio Path Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Bio Path's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Bio Path Holdings current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. As of now, Bio Path's Investments are increasing as compared to previous years.
Bio Path cash flow statement Correlations
Click cells to compare fundamentals
Bio Path Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Path cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 19.4M | (6.7M) | 10.0M | (13.4M) | (9.3M) | (8.9M) | |
| Free Cash Flow | (8.4M) | (11.0M) | (10.0M) | (15.1M) | (11.5M) | (11.0M) | |
| Change In Working Capital | (676K) | (806K) | (459K) | (2.3M) | 3.1M | 3.3M | |
| Begin Period Cash Flow | 1.0M | 20.4M | 13.8M | 23.8M | 10.4M | 6.1M | |
| Other Cashflows From Financing Activities | 1.1M | 4.3K | 4.2M | (21K) | 526K | 499.7K | |
| Depreciation | 230K | 151K | 161K | 178K | 204.7K | 179.9K | |
| Other Non Cash Items | 1.3M | 963K | 1.3M | 507K | 498K | 368.7K | |
| Total Cash From Operating Activities | (8.4M) | (11.0M) | (9.9M) | (15.1M) | (11.5M) | (11.0M) | |
| Net Income | (8.6M) | (10.9M) | (10.4M) | (13.9M) | (16.1M) | (15.3M) | |
| Total Cash From Financing Activities | 27.8M | 4.3M | 20.0M | 1.7M | 2.2M | 2.1M | |
| End Period Cash Flow | 20.4M | 13.8M | 23.8M | 10.4M | 1.1M | 999.4K | |
| Sale Purchase Of Stock | 5.1M | 1.2M | 27.8M | 4.3M | 4.9M | 7.8M | |
| Cash And Cash Equivalents Changes | (3.4M) | (5.0M) | 19.4M | (6.7M) | (6.0M) | (5.7M) | |
| Cash Flows Other Operating | (192K) | 545K | (412K) | (643K) | (578.7K) | (549.8K) | |
| Change To Netincome | 1.2M | 684K | 577K | 821K | 944.2K | 991.4K | |
| Change To Liabilities | 326K | (168K) | (84K) | (199K) | (179.1K) | (170.1K) | |
| Stock Based Compensation | 684K | 577K | 821K | 851K | 734K | 531.6K | |
| Change To Operating Activities | 335K | (508K) | (722K) | (260K) | (234K) | (245.7K) | |
| Issuance Of Capital Stock | 26.7M | 4.3M | 15.8M | 1.7M | 3.4M | 3.3M |
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.